stockportfolio.pro
Stocks / TALK vs TBPH
TALK vs TBPH
Talkspace, Inc. and Theravance Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Talkspace, Inc. (TALK) | Theravance Biopharma, Inc. (TBPH) | |
|---|---|---|
| Market cap | $0.9B | $0.8B |
| Revenue (latest FY) | $228.87M | $107.46M |
| Net income (latest FY) | $7.79M | $105.89M |
| Revenue growth (5y CAGR) | 24.6% | 8.4% |
| Net margin | 3.4% | 98.5% |
| Return on equity | 6.7% | 35.7% |
| P/E ratio | — | 7.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open TALK — free Open TBPH — freeFrequently asked questions
Which is bigger, TALK or TBPH?
Talkspace, Inc. is larger by market capitalization — $0.9B versus $0.8B.
Which grows faster, TALK or TBPH?
Over the last five fiscal years, Talkspace, Inc. grew revenue faster — 24.6%/yr versus 8.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.